Although glucocorticoids are a mainstay drug for remission induction therapy in SLE,36 this study showed no decrease in CD8+CD38+ human leucocyte antigen-DR+ T cells in patients treated with high-dose glucocorticoid monotherapy (data not shown). The gene discussed is CD38; the disease is systemic lupus erythematosus.